SLC5A2 and type 2 diabetes mellitus: Gliflozins are a novel class of anti-hyperglycemic agents used for the treatment of T2DM that selectively inhibit the SGLT2 in the kidneys, leading to an insulin-independent lowering of blood glucose levels through an enhanced daily urinary loss of up to 100 g of glucose (200–300 kcal) [17].